FDA’s June 2024 list of off-patent, off-exclusivity drugs sees rise in cancer, HIV treatments
This week PharmaCompass brings to you key highlights of the US Food and Drug Administration’s
Top drugs and pharmaceutical companies of 2019 by revenues
Acquisitions and spin-offs dominated headlines in 2019 and the tone was set very early with Bristol-
Data-integrity concerns at Baxter’s US$ 625 million buy in India; Did pharma bribes fund terrorism in Iraq?
This week, Phispers has details on the Amneal-Impax merger and an update on Allergan’s alleged
Lundbeck’s CEO to head Teva; Pfizer gets FDA warning letter for supplying faulty EpiPens
This
week, Phispers brings you news about Teva, which finally found a CEO in Kare
Schultz. Allerga